US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neo-Concept International Group Holdings Limited

0.3950

-0.0449-10.21%

Post-market: 0.40000.0050+1.27%18:04 EDT

Volume:35.77K

Turnover:14.47K

Market Cap:8.03M

PE:5.17

High:0.4100

Open:0.4099

Low:0.3903

Close:0.4399

Loading ...

Overview Company News Filings

ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Preliminary results for the year ended 31 December 2024

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

ACCESS Newswire

Shell first quarter 2025 update note

Press Release: Shell to sell interest in Colonial Enterprises Inc. to Brookfield subsidiary

Neo-Concept International Launches Les100Ciels Store in Abu Dhabi: A New Chapter in MENA!

Press Release: QT Imaging Announces Fourth Quarter and Full Year 2024 Financial Results and Provides 2025/26 Outlook

Press Release: Aptose Reports Year End 2024 Results and Corporate Highlights

Press Release: Tempest Reports Year End 2024 Financial Results and Provides Business Update

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Why Tempus AI (TEM) Went Up On Friday?

Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NCI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":0.395,"timestamp":1745265600000,"preClose":0.4399,"halted":0,"volume":35765,"hourTrading":{"tag":"盘后","latestPrice":0.4,"preClose":0.395,"latestTime":"18:04 EDT","volume":203,"amount":82.79999930999999,"timestamp":1745273059178},"delay":0,"floatShares":1726200,"shares":20320000,"eps":0.076408,"marketStatus":"Post-Mkt","change":-0.0449,"latestTime":"04-21 18:42:20 EDT","open":0.4099,"high":0.41,"low":0.3903,"amount":14473.787921,"amplitude":0.044783,"askPrice":0.4559,"askSize":100,"bidPrice":0.38,"bidSize":150,"shortable":0,"etf":0,"ttmEps":0.076408,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":0.4399,"dividendRate":0.506329,"preHourTrading":{"tag":"盘前","latestPrice":0.4,"preClose":0.4,"latestTime":"08:00 EDT","volume":2,"amount":0.8,"timestamp":1745236803068},"postHourTrading":{"tag":"盘后","latestPrice":0.4,"preClose":0.395,"latestTime":"18:04 EDT","volume":203,"amount":82.79999930999999,"timestamp":1745273059178},"volumeRatio":0.354077},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":1726200,"roa":"6.28%","roe":"58.31%","lyrEps":0.031396,"volumeRatio":0.354077,"shares":20320000,"dividePrice":0.2,"high":0.41,"amplitude":0.044783,"preClose":0.4399,"low":0.3903,"week52Low":0.3501,"pbRate":"1.25","psRate":"0.35","week52High":11.39,"institutionHeld":0.7857,"latestPrice":0.395,"committee":0.2,"eps":0.076408,"divideRate":0.506329,"volume":35765,"delay":0,"ttmEps":0.076408,"open":0.4099,"prevYearClose":0.66,"prevWeekClose":0.4399,"prevMonthClose":0.48,"prevQuarterClose":0.48,"fiveDayClose":0.43,"twentyDayClose":0.4159,"sixtyDayClose":0.68},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527413733","title":"ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527413733","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527413733?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"Study conducted under the CRADA agreement between NCI and Oryzon. MADRID and CAMBRIDGE, Mass., April 15, 2025  -- Oryzon Genomics, S.A. , a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in a Phase I/II trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with immune checkpoint inhibitors  in first line small cell lung cancer  patients with extensive disease, sponsored by the National Cancer Institute , part of the National Institutes of Health. This is the first clinical trial testing the combination of iadademstat with ICI.About OryzonFounded in 2000 in Barcelona, Spain, Oryzon  is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oryzon-announces-first-patient-dosed-120000598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4613","BK4607","BK4156","SSI","BK4588","BK4116","BK4202","LU2286300806.USD","BK4554","BK4548","NCI","NET","ORYZF","BK4139","BK4560"],"gpt_icon":0},{"id":"2527163224","title":"Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2527163224","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527163224?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:30","pubTimestamp":1744716600,"startTime":"0","endTime":"0","summary":"New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ. Finally, RNA sequencing of LM cells showed early induction of apoptosis, with an innate immune response followed by an increase in T cells and an adaptive immune response by Day 28. Further details can be found here; the Company will provide additional data and explanation following the meeting.About Leptomeningeal Metastases LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid  and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3-5% of breast cancer patients developing LM. Additionally, lung cancer, GI cancers and melanoma can also spread to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/plus-therapeutics-presents-data-highlighting-113000997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","CNS","NCI","BK4007","PSTV","LENZ","CSF","BK4139","BK4202"],"gpt_icon":0},{"id":"2526498953","title":"Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2526498953","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526498953?lang=en_us&edition=fundamental","pubTime":"2025-04-10 04:30","pubTimestamp":1744230600,"startTime":"0","endTime":"0","summary":"Amezalpat  is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma ; global investigator support in place. Awarded both Orphan Drug & Fast Track designations for amezalpat based on positive randomized Phase 2 data in first-line HCC. Received FDA “Study May Proceed” letter for TPST-1495 in a Phase 2 trial for the treatment of familial adenomatous polyposis ; data expected 2026. The company has not set a timetable for completion of the process for evaluating strategic alternatives and does not intend to disclose further developments or guidance on the status of its programs or the process for evaluating strategic alternatives unless and until it is determined that further disclosure is appropriate or necessary. No agreement providing for any transaction has been reached and there can be no assurances that any transaction will result from the process for evaluating strategic alternatives. If the process for evaluating strategic alterna","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempest-announces-plan-explore-strategic-203000016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","OS","TPST","HCC","BK4202","BK4097","BK4139","BK4006"],"gpt_icon":0},{"id":"2526352564","title":"Preliminary results for the year ended 31 December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2526352564","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526352564?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:00","pubTimestamp":1744196400,"startTime":"0","endTime":"0","summary":"~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of 44% to 128.8 million compared to 2023, organic r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/09/3058256/0/en/Preliminary-results-for-the-year-ended-31-December-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4019","CDMO","NCI","BK4159","ESGR","CAGR","BK4139","BK4229","AGM","CET","BK4202","CFO"],"gpt_icon":0},{"id":"2525092892","title":"Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2525092892","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525092892?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:30","pubTimestamp":1744115400,"startTime":"0","endTime":"0","summary":"Gelclair is the company's third commercialized prescription product. Oral mucositis, also called \"chemo mouth,\" a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force. Napo's core target patient audiences for Gelclair are head and neck cancer patients and bone marrow transplant patients. \"Cancer is chaotic, because patients feel a loss of control - over their life, their treatment, and their supportive care needs,\" said Conte. \"Jaguar's mission is to change patients' lives for the better, especially in the area of supportive care for complex disease states like cancer. We look forward to driving awareness among the oncology nursing community at ONS about Gelclair. Oral mucositis, also called \"chemo mouth,\" is among the most common, painful, and debilitating cancer treatment-related side effects, and it is undertreated and underappreciated. We believe we can hel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/napo-pharmaceuticals-jaguar-health-family-123000734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JAGX","BK4007","NCI","BK4202"],"gpt_icon":0},{"id":"2525063796","title":"Shell first quarter 2025 update note","url":"https://stock-news.laohu8.com/highlight/detail?id=2525063796","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525063796?lang=en_us&edition=fundamental","pubTime":"2025-04-07 14:00","pubTimestamp":1744005600,"startTime":"0","endTime":"0","summary":"The following is an update to the first quarter 2025 outlook and gives an overview of our current expectations for the first quarter. Outlooks presented may vary from the actual first quarter 2025 res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056424/0/en/Shell-first-quarter-2025-update-note.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","NCI","BK4202","MT","BK4561"],"gpt_icon":0},{"id":"2524727468","title":"Press Release: Shell to sell interest in Colonial Enterprises Inc. to Brookfield subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2524727468","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524727468?lang=en_us&edition=fundamental","pubTime":"2025-04-04 17:34","pubTimestamp":1743759240,"startTime":"0","endTime":"0","summary":"HOUSTON, April 3, 2025 /PRNewswire/ -- Shell Midstream Operating LLC. , a subsidiary of Shell plc , has agreed to sell its. AcquireCo LLC, a wholly owned subsidiary of Brookfield Infrastructure. \"This divestment reflects our focus on performance, discipline and. simplification,\" said Andrew Smith, President of Shell Trading & Supply.\"It will allow us to concentrate on areas where we have scale and. The transaction is subject to regulatory approvals and is expected to. -- Together with Shell, the co-owners of Colonial Enterprises, Inc. have. agreed to sell 100% of their Colonial shares to Brookfield. Colonial is. -- The sale values Shell's share of Colonial at $1.45 billion, inclusive of. -- Shell Midstream Operating LLC is an indirect, wholly owned subsidiary of. Shell Pipeline Company LP, and the largest pipeline operator in the Gulf. and employs more than 12,000 people who work to provide a secure supply. Shell's U.S. portfolio of operated companies and interests consists of. The com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIP","BK4588","LU0278409577.USD","LU0098860793.USD","LU0320765646.SGD","LU2236285917.USD","LU0300736492.USD","NCI","BK4550","LU1162221912.USD","BK4208","SHEL","BK4585","BK4202","LU0300736062.USD","BK4201"],"gpt_icon":0},{"id":"2524119809","title":"Neo-Concept International Launches Les100Ciels Store in Abu Dhabi: A New Chapter in MENA!","url":"https://stock-news.laohu8.com/highlight/detail?id=2524119809","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524119809?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:00","pubTimestamp":1743512400,"startTime":"0","endTime":"0","summary":"HONG KONG, April 01, 2025  -- Neo-Concept International Group Holdings Limited  is excited to announce the soft opening of its very first Les100Ciels store in the Middle East and North Africa  region!Located at The Galleria Al Maryah Island in Abu Dhabi, which took place on March 27, 2025.This milestone marks a significant leap forward in our journey, following the successful launch of our joint venture with Liwa Trading Enterprises LLC, designed to boost our retail footprint in the vibrant MENA markets.The debut of The Galleria store, coupled with our new Middle East e-shop, is a pivotal step in our mission to deliver an outstanding shopping experience—both online and in-store—for our customers in the MENA region.NCI is dedicated to minimizing its environmental footprint by implementing various eco-friendly practices. It prioritizes recycling, clean processes, and traceable sourcing as part of its commitment to reducing environmental imp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neo-concept-international-launches-les100ciels-130000750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","BK4202"],"gpt_icon":0},{"id":"2523094952","title":"Press Release: QT Imaging Announces Fourth Quarter and Full Year 2024 Financial Results and Provides 2025/26 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2523094952","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523094952?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:33","pubTimestamp":1743424380,"startTime":"0","endTime":"0","summary":"Generated Sales of Twelve Scanners with Revenue of Approx. $5 Million and with 54% Gross Margin in 2024. Announced Insiders PIPE investment of $2.56 Million, fully funded by the QTI Board of Directors members and Management. Announced the Closing of $10.1 million Lynrock Lake Term Loan, of which $5.4 million is for Working Capital Purposes. Announced Clearing of All Its Short-Term Debt Liabilities. Closed Exclusive Distribution Agreement in USA with NXC Imaging. Entered into Manufacturing Agreement with Canon Medical Systems Corporation. Forecasts Solid Revenue Growth of $18 million and $27 million for 2025 and 2026, respectively. QT Imaging Holdings, Inc.  , a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the four quarter and full year 2024 and reiterated the strong forecast for 2025 and 2026.million for the fourth quarter of 2023. Commercial revenue was $4.9. million for the yea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","NCI","TM","03160","BK4082","BK4099","BK4202","BK4604","NQmain","BK4555","QTIH","BK4588"],"gpt_icon":0},{"id":"2522432573","title":"Press Release: Aptose Reports Year End 2024 Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522432573","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522432573?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:01","pubTimestamp":1743163260,"startTime":"0","endTime":"0","summary":"Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial. Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy. SAN DIEGO and TORONTO, March 28, 2025  -- Aptose Biosciences Inc.  , a clinical-stage precision oncology company developing a tuspetinib -based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia , today announced financial results for the year ended December 31, 2024, and provided a corporate update.\"During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax  and azacitidine  for frontline treatment of newly diagnosed acute myeloid leukemia ,\" said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. \"Tuspetinib brings favorable safety and broad activity across AML genetic subtypes to the TUS+VEN+AZA triplet therapy, which already has achieved complete remissions  in difficult-to-t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USJW.SI","APTOF","BK4139","USAW.SI","QLD","NVIW.SI","SQQQ","PSQ","TSYW.SI","NQmain","ASH","QID","LU2463526074.USD","MNQmain","APTO","BK4109","BK4202","TQQQ","NCI",".IXIC"],"gpt_icon":1},{"id":"2522853184","title":"Press Release: Tempest Reports Year End 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522853184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522853184?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:10","pubTimestamp":1743106200,"startTime":"0","endTime":"0","summary":"-- Granted Both Orphan Drug & Fast Track designations for Amezalpat  for the treatment of patients with Hepatocellular Carcinoma . -- Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial. -- Received FDA \"Study May Proceed\" letter for Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis . \"2024 was another year filled with significant progress and milestone achievements that position Tempest for a successful future,\" said Stephen Brady, president and chief executive officer of Tempest. \"Despite challenging capital markets, our lean team excelled, reporting key OS data from the ongoing randomized Phase 2 trial of amezalpat in first-line hepatocellular carcinoma. As previously announced, we have secured broad regulatory agreement with both the FDA and EMA on the Phase 3 plan and received both Orphan Drug and Fast Track designations from the FDA. We also advanced our second clinical program, TPST","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","OS","TPST","R","HCC","BK4232","BK4202","BK4022","BK4097","BK4139","BK4006"],"gpt_icon":0},{"id":"2522306967","title":"Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225","url":"https://stock-news.laohu8.com/highlight/detail?id=2522306967","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522306967?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:45","pubTimestamp":1743079500,"startTime":"0","endTime":"0","summary":"- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models. - ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model. - Initial ATNM-400 preclinical data to be presented at AACR including results in Pluvicto resistant prostate cancer models. ATNM-400 selectively binds to prostate cancer cells, undergoes rapid internalization, and induces dose-depen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-atnm-400-124500358.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-atnm-400-124500358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","NCI","ATNM","BK4202","BK4139","CR","HMA"],"gpt_icon":0},{"id":"2522615804","title":"Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522615804","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522615804?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:15","pubTimestamp":1742994900,"startTime":"0","endTime":"0","summary":"– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo –。– CABOMETYX is now the first and only systemic treatment that is FDA approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status –。– Exelixis is prepared to immediately support these new indications –。ALAMEDA, Calif., March 26, 2025----Exelixis, Inc.  today announced that the U.S. Food and Drug Administration  has approved CABOMETYX  for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors ; and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET . NET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-announces-u-fda-approval-131500269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AEIS","IE0031619046.USD","BK4585","BK4190","NET","HCC","IE00B66KJ199.SGD","BK4532","BK4006","IE00B7SZL793.SGD","DTC","BK4554","BK4139","BK4560","LU2286300806.USD","BK4613","NCI","IE00B19Z4B17.USD","BK4588","EXEL","BK4607","BK4548","RCC","BK4116","BK4157","BK4202"],"gpt_icon":0},{"id":"2522880537","title":"Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2522880537","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522880537?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:45","pubTimestamp":1742993100,"startTime":"0","endTime":"0","summary":"- Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical data expected in 2025 supporting each addressable market. - Presentation follows Investor KOL Event and Company Update on March 25th. NEW YORK, March 26, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. , a pioneer in the development of targeted radiotherapies, announced it will be presenting a business update today at Trump Mar-a-Lago Club, Florida. This presentation follows an Investor KOL Call and Company Update hosted by Actinium on Tuesday, March 25th highlighting its revitalized clinical programs and expanded market opportunities. Actinium's Investor KOL Call and Company Update can be accessed for replay here.Generate clinical data in first non-malignant indication from sickle cell disease allogeneic stem cell transplant trial at Columbia University","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-present-business-trump-124500258.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-present-business-trump-124500258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","BK4161","BK4202","CR","ATNM","BK4139","HMA"],"gpt_icon":0},{"id":"2522022501","title":"Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022501","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022501?lang=en_us&edition=fundamental","pubTime":"2025-03-25 18:00","pubTimestamp":1742896800,"startTime":"0","endTime":"0","summary":"- Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning. - Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin to highlight Actimab-A clinical results, mutation agnostic mechanism and backbone therapy potential. - Clinical proof of concept data from frontline AML trial under NCI CRADA, Actimab-A solid tumor program with PD-1 checkpoint inhibitors and Iomab-ACT commercial CAR-T trial together with other expected 2025 milestones to be outlined. - Actinium to highlight manufacturing infrastructure development activity to support revitalized clinical programs. Actinium's company update will highlight the 3 separate potential multi-billion-dollar blockbuster market opportunities being pursued with its targeted radiotherapies including the following:. - Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies including AML and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-kol-investor-100000655.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-kol-investor-100000655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ATNM","BK4218","HMA","BK4161","NCI","BK4590","KOL","BK4202","BK4561","HST","BK4144","ET","BK4581","BK4585","BK4181","BK4588","CR"],"gpt_icon":0},{"id":"2522707005","title":"Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707005","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707005?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:15","pubTimestamp":1742847300,"startTime":"0","endTime":"0","summary":"NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. , a pioneer in the development of targeted radiotherapies,today announced it has entered into an agreement for the supply of Actinium-225  with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials.Targeted radiotherapies using Ac-225 have shown great promise in the treatment of cancer. The radioisotope releases powerful alpha particles with high energy and low penetration depth, enabling precise targeting of tumor cells, including hard-to-reach micrometastases, while minimizing effects on surrounding healthy tissue. Actimab-A is an Ac-225 based radiotherapy agent, directed against CD33, a receptor overexpressed in patients with acute myeloid leukemia  and other myeloid indications.E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-supply-agreement-201500023.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-supply-agreement-201500023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","ATNM","HMA","BK4139","NCI","CR","BK4202"],"gpt_icon":0},{"id":"2521976342","title":"Why Tempus AI (TEM) Went Up On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521976342","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521976342?lang=en_us&edition=fundamental","pubTime":"2025-03-22 15:15","pubTimestamp":1742627713,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Stocks Lead Friday’s Charge. In this article, we are going to take a look at where Tempus AI  stands against other stocks that lead Friday’s charge.The stock market finished in the green territory on Friday, albeit muted trading persisted over the lack of catalysts to fuel investing appetite.The tech-heavy Nasdaq led gains among Wall Street’s benchmark indices, finishing up by 0.52 percent. Meanwhile, both the Dow Jones and S&P 500 ended the week eking out 0.08-percent gains.Ten companies mirrored the broader market optimism, finishing the week with modest gains. In this article, we have identified today’s top performers and detailed the reasons behind their gains.To come up with the list, we considered only the stocks with $2 billion in market capitalization and $5 million in trading volume.Cathie Wood, co-founder and CEO of Ark Invest, for instance, included TEM in her portfolio of AI stocks.Earlier this month, TEM announced the acquisition of Deep ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-tempus-ai-tem-went-071513790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","IE00BVYPNW00.USD","LU1861559042.SGD","PSQ","BK4611","QLD","TSYW.SI","IE00BGHQF631.EUR","LU2355687059.USD","USJW.SI","TQQQ","BK4202","TEM","BK4096","LU1861558580.USD","NCI","BK4585","BK4533","BK4121","USAW.SI","SG9999011175.SGD","BK4597","NQmain","IE00B42XCP33.USD","BK4543","NVIW.SI","BK4613","MNQmain","QID","IE00B3PB1722.GBP","IE00BVYPNV92.GBP",".IXIC","SG9999003800.SGD","SQQQ","EMR","IE00BDGV0183.EUR"],"gpt_icon":1},{"id":"2521151496","title":"Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521151496","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521151496?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in Acute Myeloid Leukemia  with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 --. -- Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009  in r/r AML -- Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 --. Announced Positive Outcome of Interim Analysis for Phase 3 REGAL Trial of GPS in AML: The interim futility, efficacy, and safety analysis was designed to assess whether the therap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","LU2355687059.USD","NCI","LU1699723380.USD","OS","ODD","BK4181","INN","LU0985320562.USD","SLS","BK4097","BK4588","BK4232","BK4022","BK4107","LU1571399168.USD","BK4585","BK4533","LU2463526074.USD","BK4161","PR","ALL","ORR","BK4139","ASH","BK4218","CR","BK4109","BK4202","R","BK4183"],"gpt_icon":0},{"id":"2520591458","title":"Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2520591458","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520591458?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:30","pubTimestamp":1742470200,"startTime":"0","endTime":"0","summary":"REYOBIQ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM)  HOUSTON, March  20, 2025  (GLOBE NEWSWIRE) -- Plus ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/20/3046120/0/en/Plus-Therapeutics-Introduces-REYOBIQ-FDA-Accepted-Proprietary-Name-for-Lead-Drug-Candidate.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","LENZ","BK4139","NCI","BK4202","BK4135"],"gpt_icon":0},{"id":"2520927182","title":"Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520927182","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520927182?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387400,"startTime":"0","endTime":"0","summary":"-  Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning. -  Clinical proof of concept data expected in 2H:2025 from Actimab-A combination with blockbuster immunotherapies KEYTRUDA and OPDIVO in solid tumor indications. - Actimab-A expanded into frontline AML in triplet combination with Venetoclax and ASTX-727, Taiho Oncology's hypomethylating agent, under NCI CRADA with initial clinical data expected by year-end 2025. - Iomab-ACT commercial CAR-T trial to initiate patient enrollment with clinical proof of concept data expected in 2H:2025; Iomab-ACT sickle cell disease trial expected to initiate in 1H:2025. Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies including AML and myelodysplastic syndromes  across multiple treatment settings. Sandesh Seth, Actinium's Chairman and CEO, said, \"We have made significant progress across our pipeline ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-investor-kol-123000877.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-investor-kol-123000877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","BK4585","ACT","NCI","KOL","ATNM","BK4588","BK4202","BK4181","BK4218","BK4139","HST","CR","HMA"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":110,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2025-04-17","current":5.733501,"percent":0.087336,"low":-615.963293,"twenty":6.823071,"median":16.327956,"eighty":24.52062,"high":50.080918,"avg":6.908672,"sd":53.27237,"marketCap":8128000},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":28.783514,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":16256000},{"date":"2024-06-07","current":28.579978,"twenty":-81.702314,"median":24.992177,"eighty":34.642796,"marketCap":16154400},{"date":"2024-06-14","current":31.815689,"twenty":-79.845114,"median":25.185699,"eighty":33.392506,"marketCap":17983200},{"date":"2024-06-21","current":25.826264,"twenty":-75.704037,"median":25.951163,"eighty":31.815689,"marketCap":14610080},{"date":"2024-06-28","current":24.010495,"twenty":-75.181642,"median":25.826264,"eighty":31.166365,"marketCap":13573760},{"date":"2024-07-05","current":21.847045,"twenty":-74.134092,"median":24.992177,"eighty":30.05711,"marketCap":12350496},{"date":"2024-07-12","current":24.005484,"twenty":-72.824666,"median":24.22361,"eighty":29.406809,"marketCap":13573760},{"date":"2024-07-15","current":23.309684,"twenty":-72.571072,"median":24.010495,"eighty":29.29759,"marketCap":13183616},{"date":"2024-08-02","current":17.799213,"twenty":-72.317479,"median":24.00799,"eighty":29.18837,"marketCap":10054336},{"date":"2024-08-09","current":15.712059,"twenty":-71.040839,"median":23.456094,"eighty":28.858081,"marketCap":8900160},{"date":"2024-08-16","current":14.71315,"twenty":-69.000048,"median":23.177414,"eighty":28.661392,"marketCap":8331200},{"date":"2024-08-23","current":15.475212,"twenty":-65.359249,"median":22.360574,"eighty":28.479131,"marketCap":8761984},{"date":"2024-08-30","current":15.211668,"twenty":-16.796281,"median":21.73132,"eighty":28.375818,"marketCap":8611616},{"date":"2024-09-06","current":15.60865,"twenty":14.533412,"median":17.564477,"eighty":28.127716,"marketCap":8839200},{"date":"2024-09-13","current":18.316746,"twenty":14.714645,"median":17.091682,"eighty":27.226945,"marketCap":10363200},{"date":"2024-09-20","current":30.136472,"twenty":14.729124,"median":17.451967,"eighty":27.226945,"marketCap":17068800},{"date":"2024-09-27","current":18.155945,"twenty":14.756986,"median":17.799213,"eighty":26.316487,"marketCap":10304272},{"date":"2024-10-04","current":24.668714,"twenty":14.779837,"median":18.134605,"eighty":27.226945,"marketCap":14022832},{"date":"2024-10-11","current":19.411936,"twenty":14.800605,"median":18.316746,"eighty":26.316487,"marketCap":11029696},{"date":"2024-10-18","current":27.159393,"twenty":14.841085,"median":19.188638,"eighty":26.316487,"marketCap":15422880},{"date":"2024-10-25","current":22.801653,"twenty":14.96086,"median":20.067961,"eighty":27.538745,"marketCap":12954000},{"date":"2024-10-31","current":26.444278,"twenty":15.097424,"median":21.615595,"eighty":28.23974,"marketCap":15016480},{"date":"2024-11-08","current":25.398607,"twenty":15.188698,"median":21.880614,"eighty":27.72766,"marketCap":14427200},{"date":"2024-11-15","current":22.207911,"twenty":15.214052,"median":22.207911,"eighty":27.409251,"marketCap":12598400},{"date":"2024-11-22","current":20.742686,"twenty":15.227723,"median":22.212919,"eighty":27.092873,"marketCap":11765280},{"date":"2024-11-29","current":19.71984,"twenty":15.244259,"median":22.031838,"eighty":26.826792,"marketCap":11184128},{"date":"2024-12-06","current":19.342155,"twenty":15.419442,"median":21.847045,"eighty":26.825987,"marketCap":10972800},{"date":"2024-12-13","current":18.931587,"twenty":15.475212,"median":20.935809,"eighty":26.444278,"marketCap":10749280},{"date":"2024-12-20","current":16.81288,"twenty":15.549996,"median":20.067961,"eighty":26.379894,"marketCap":9550400},{"date":"2024-12-27","current":7.581302,"twenty":15.240125,"median":20.023482,"eighty":26.25308,"marketCap":10741152},{"date":"2025-01-03","current":8.618162,"twenty":15.140189,"median":19.71984,"eighty":26.21899,"marketCap":12196064},{"date":"2025-01-10","current":10.05795,"twenty":14.800605,"median":19.685908,"eighty":26.181452,"marketCap":14224000},{"date":"2025-01-17","current":8.786233,"twenty":14.714645,"median":19.468094,"eighty":26.125394,"marketCap":12415520},{"date":"2025-01-24","current":9.780279,"twenty":10.25185,"median":19.354401,"eighty":26.087984,"marketCap":13817600},{"date":"2025-01-31","current":8.55813,"twenty":9.931507,"median":18.990258,"eighty":25.926183,"marketCap":12088368},{"date":"2025-02-07","current":8.034161,"twenty":9.67709,"median":18.942456,"eighty":25.806345,"marketCap":11354816},{"date":"2025-02-14","current":7.429972,"twenty":9.170381,"median":18.736365,"eighty":25.661057,"marketCap":10499344},{"date":"2025-02-21","current":7.182682,"twenty":8.786233,"median":18.611629,"eighty":25.398607,"marketCap":10166096},{"date":"2025-02-28","current":6.088957,"twenty":8.49005,"median":18.298903,"eighty":25.263582,"marketCap":8617712},{"date":"2025-03-07","current":6.285152,"twenty":8.101774,"median":18.113266,"eighty":25.252549,"marketCap":8900160},{"date":"2025-03-14","current":5.596631,"twenty":7.768683,"median":17.68941,"eighty":25.185699,"marketCap":7924800},{"date":"2025-03-21","current":6.28575,"twenty":7.480228,"median":17.54621,"eighty":25.06182,"marketCap":8900160},{"date":"2025-03-28","current":6.3175,"twenty":7.319362,"median":17.202773,"eighty":24.992177,"marketCap":8940800},{"date":"2025-04-04","current":6.433722,"twenty":7.066391,"median":16.81288,"eighty":24.761928,"marketCap":9104010},{"date":"2025-04-11","current":7.43656,"twenty":6.901399,"median":16.523806,"eighty":24.668714,"marketCap":10546080},{"date":"2025-04-17","current":5.733501,"twenty":6.823071,"median":16.327956,"eighty":24.52062,"marketCap":8128000}],"updateTime":1745258163327}}}